BVT Knock-Out LLY/ DE000VD0RXC1 /
2024-11-15 2:49:39 PM | Chg.-0.61 | Bid10:00:37 PM | Ask10:00:37 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
13.49EUR | -4.33% | - Bid Size: - |
- Ask Size: - |
Eli Lilly and Co | 636.88 USD | 2078-12-31 | Call |
Newsfile Corp
09-16
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Newsfile Corp
08-28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
08-27
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-14
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
08-14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-08
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-07
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
08-06
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
08-06
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
08-02
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-01
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
08-01
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives